ALNY News and Press, Alnylam Pharmaceuticals Inc. From 08/03/21

Alnylam Pharmaceuticals, Inc. Q2 2021 Earnings Conference Call Aug 3, 2021 8:30 AM ET Company Participants Christine Lindenboom - Investor Relations John Maraganore - Chief Executive Officer Tolga Tanguler - Chief Commercial Officer Akshay Vaishnaw - President of Research and Development Jeff...

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Alnylam Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation

Alnylam Pharmaceuticals (NASDAQ:ALNY) exceeded analyst expectations for Q2 2021 as its revenue for the quarter more than doubled from the previous year prompting the management to raise the guidance for 2021. The company reported $220.6M in revenue in Q2 2021 with ~112% YoY growth driven...

Alnylam Pharmaceuticals (NASDAQ:ALNY): Q2 Non-GAAP EPS of -$1.30 misses by $0.05; GAAP EPS of -$1.61 beats by $0.02. Revenue of $220.55M (+112.1% Y/Y) beats by $26.89M. FY21 Guidance: Combined net product revenues for ONPATTRO, GIVLAARI and OXLUMO: $640M - $665M from previous outlook of $610M...

− Achieved Second Quarter 2021 Combined Net Product Revenues of $161 Million for ONPATTRO ® , GIVLAARI ® , and OXLUMO ® – − Advanced Vutrisiran with New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (...

ALNY,AME,AQUA,ARNC,ATI,ATKR,AVNS,BABA,BEN,BHC,BLD,BP,CLX,CMI,COP,CRSR,CWEN,CWH,DD,DEA,DISCA,DNB,ESPR,ETN,ETRN,EXPD,FI,FIS,HEES,HLNE,HSC,HSIC,HSKA,IAA,IGT,INCY,INGR,IPGP,IT,KKR,LCII,LDOS,LGIH,LLY,LPX,MAR,MIME,MTRN,NKLA,NNN,NVT,OMI,OPCH,PBI,PCRX,PEG,PSX,PSXP,RCM,RHP,RL,ROCK,SABR,SAGE,SEE,SUN,SW...

− Agreement Combines PeptiDream’s Peptide Discovery Platform to Identify High Affinity Peptide Ligands with Alnylam’s Expertise in siRNA-Conjugate-Based Delivery and in Developing and Commercializing RNAi Therapeutics − Alnylam Pharmaceutica...

Alnylam Pharmaceuticals (NASDAQ:ALNY) has lost ~1.4% in the pre-market after the company announced topline results from a Phase 3 study which was designed to evaluate lumasiran in patients with primary hyperoxaluria type 1 (PH1) associated with a decline in renal function. The ...

- Results Showed Substantial Reductions in Plasma Oxalate Relative to Baseline in PH1 Patients with Severe Renal Impairment, Including Those on Dialysis, and an Encouraging Safety and Tolerability Profile - - Alnylam Intends to File Supplemental Regulatory Applications with th...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2021 on Tuesday, August 3, 2021, before the U.S. financial markets open. Management will provide an u...